| 1 |
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew George Robinson et al. · New England Journal of Medicine
Open access |
9 Oct 2016 |
10,303 |
| 2 |
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
David Cunningham, William Allum, Sally Patricia Stenning et al. · New England Journal of Medicine
|
6 Jul 2006 |
6,432 |
| 3 |
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al. · New England Journal of Medicine
Open access |
11 Sep 2017 |
5,453 |
| 4 |
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine
Open access |
21 Jul 2004 |
5,071 |
| 5 |
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann Sebastian De Bono et al. · New England Journal of Medicine
Open access |
25 May 2011 |
4,448 |
| 6 |
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al. · Journal of Clinical Oncology
Open access |
19 Apr 2010 |
4,301 |
| 7 |
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al. · Nature
Open access1,384 authors |
5 Feb 2020 |
3,854 |
| 8 |
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin et al. · New England Journal of Medicine
Open access |
28 Sep 2019 |
3,784 |
| 9 |
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan R. Robinson et al. · Cell
Open access |
May 2015 |
3,727 |
| 10 |
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy Anthony Yap et al. · New England Journal of Medicine
Open access |
24 Jun 2009 |
3,663 |
| 11 |
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris C. Parker et al. · New England Journal of Medicine
|
17 Jul 2013 |
3,410 |
| 12 |
Pan-cancer analysis of whole genomes
Lauri A. Aaltonen et al. · Nature
Open access1,324 authors |
5 Feb 2020 |
3,360 |
| 13 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Ann Burtness et al. · The Lancet
Open access219 authors |
Nov 2019 |
3,344 |
| 14 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian De Bono, Stéphane Marie. Oudard, Mustafa Özgüroğlu et al. · The Lancet
|
Oct 2010 |
3,328 |
| 15 |
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline B. Kuchenbaecker et al. · JAMA
Open access |
20 Jun 2017 |
2,963 |
| 16 |
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore et al. · New England Journal of Medicine
Open access |
21 Oct 2018 |
2,927 |
| 17 |
Renal cell carcinoma
James J.-D. Hsieh, Mark P. Purdue, Sabina Signoretti et al. · Nature Reviews Disease Primers
ReviewOpen access |
9 Mar 2017 |
2,857 |
| 18 |
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Debbie Saslow, Carla Boetes, Wylie Burke et al. · CA A Cancer Journal for Clinicians
Open access |
Mar 2007 |
2,657 |
| 19 |
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurélien Marabelle et al. · The Lancet Oncology
Open access |
10 Sep 2020 |
2,600 |
| 20 |
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
16 Feb 2019 |
2,590 |
| 21 |
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
John B.A.G. Haanen, Franck Carbonnel, Caroline Robert et al. · Annals of Oncology
Open access |
5 May 2017 |
2,385 |
| 22 |
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
David Cunningham, Naureen Starling, Sheela Rao et al. · New England Journal of Medicine
|
2 Jan 2008 |
2,326 |
| 23 |
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber et al. · New England Journal of Medicine
Open access |
10 Sep 2017 |
2,249 |
| 24 |
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Joaquı́n Mateo et al. · New England Journal of Medicine
Open access |
28 Oct 2015 |
2,220 |
| 25 |
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Bryan J. Schneider et al. · Journal of Clinical Oncology
Open access |
Nov 2021 |
2,212 |
| 26 |
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Georgios Vlachogiannis et al. · Science
Open access |
22 Feb 2018 |
2,171 |
| 27 |
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T.A. van der Graaf et al. · The Lancet
Open access |
May 2012 |
2,123 |
| 28 |
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Rob Glynne‐Jones, Lucjan Stanislaw Wyrwicz, Emmanuel Tiret et al. · Annals of Oncology
Open access |
5 May 2017 |
2,098 |
| 29 |
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
M. Dowsett et al. · JNCI Journal of the National Cancer Institute
Open access |
29 Sep 2011 |
2,020 |
| 30 |
Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology
Dow‐Mu Koh, David J. Collins · American Journal of Roentgenology
|
22 May 2007 |
1,998 |
| 31 |
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas David James et al. · The Lancet
Open access |
21 Dec 2015 |
1,985 |
| 32 |
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Éric Pujade-Lauraine et al. · The Lancet Oncology
Open access121 authors |
25 Jul 2017 |
1,891 |
| 33 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas David James et al. · New England Journal of Medicine
Open access |
3 Jun 2017 |
1,806 |
| 34 |
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Saddia Asghar, Agnieszka Katarzyna Witkiewicz, Nicholas C. Turner et al. · Nature Reviews Drug Discovery
ReviewOpen access |
30 Jan 2015 |
1,805 |
| 35 |
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David Michael Hyman et al. · New England Journal of Medicine
Open access |
19 Aug 2015 |
1,756 |
| 36 |
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck, Delvys Rodríguez‐Abreu, Andrew George Robinson et al. · Journal of Clinical Oncology
Open access |
8 Jan 2019 |
1,740 |
| 37 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E.W. Cohen et al. · The Lancet
Open access113 authors |
30 Nov 2018 |
1,731 |
| 38 |
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
Christopher M. Nutting, James P. Morden, Kevin Joseph Harrington et al. · The Lancet Oncology
Open access |
14 Jan 2011 |
1,721 |
| 39 |
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elizabeth Catherine Smyth, Marcel Verheij, William Allum et al. · Annals of Oncology
Open access |
Sep 2016 |
1,612 |
| 40 |
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan et al. · Nature reviews. Cancer
ReviewOpen access |
23 Sep 2011 |
1,520 |
| 41 |
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
Georgina Venetia Long et al. · New England Journal of Medicine
Open access |
10 Sep 2017 |
1,501 |
| 42 |
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
Joanne Haviland, John R. Owen, John A. Dewar et al. · The Lancet Oncology
Open access |
18 Sep 2013 |
1,479 |
| 43 |
The evolutionary history of lethal metastatic prostate cancer
ICGC Prostate UK Group et al. · Nature
Open access |
31 Mar 2015 |
1,466 |
| 44 |
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi, Vanna Chiarion‐Sileni, Rene C. Gonzalez et al. · The Lancet Oncology
|
22 Oct 2018 |
1,426 |
| 45 |
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Nicoletta Colombo et al. · Annals of Oncology
Open access |
4 Dec 2015 |
1,411 |
| 46 |
Colorectal cancer
David Cunningham, Wendy S. Atkin, Heinz‐Josef Lenz et al. · The Lancet
|
Mar 2010 |
1,364 |
| 47 |
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Paul Dearnaley et al. · The Lancet Oncology
Open access |
22 Jun 2016 |
1,350 |
| 48 |
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi Krishna Murthy et al. · New England Journal of Medicine
Open access |
11 Dec 2019 |
1,345 |
| 49 |
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
John B.A.G. Haanen, Michel Obéid, Lavinia Anne Spain et al. · Annals of Oncology
Open access |
18 Oct 2022 |
1,285 |
| 50 |
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al. · Nature Genetics
Open access |
2 Feb 2014 |
1,271 |